Veracyte
VCYT
43.16
-1.49
-3.34%
Veracyte
US · VCYT
#2330 by market cap
Listed 1970
43.16
-1.49
-3.34%
Live - 5344 symbols - heartbeat 5s ago
· 2026-10-08 06:26
Pre-market
42.82
-0.79%
After-hours
43.16
0.00%
Overnight
43.00
-0.37%
- Market cap
- 3.47B
- P/E (TTM)i
- 30.83
- P/Bi
- 2.50
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on VCYT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.0 percentage points.
Institutional ownership
- Held by institutions
- 111.18% -1.02pp
- Institutions
- 441 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund99.94%
Hedge Fund3.94%
Public Company3.85%
Government Pension Fund1.63%
Private Company0.72%
Individual/Insider0.59%
Insurance Company0.50%
VC/PE Fund0.34%
Sovereign Wealth Fund0.12%
Top holders as of 2026-06-30
BlackRock
16.78% · 13.49M sh
FMR
9.58% · 7.70M sh
Artisan Partners Limited Partnership
6.89% · 5.54M sh
Vanguard Portfolio Management, LLC
5.87% · 4.72M sh
State Street Global Advisors
5.84% · 4.70M sh
Vanguard Capital Management, LLC
5.17% · 4.16M sh
Dimensional Fund Advisors
3.52% · 2.83M sh
First Trust Advisors L.P.
3.12% · 2.51M sh
ARK Investment Management LLC
2.86% · 2.30M sh
Wellington Management Group
2.83% · 2.27M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Marc Stapley | Chief Executive Officer | 0.20% |
| Robert Epstein | Independent Chairperson | 0.07% |
| Eliav Barr | Independent Director | 0.06% |
| Muna Bhanji | Independent Director | 0.05% |
| Rebecca Chambers | Chief Financial Officer | 0.05% |
| Evan Jones | Independent Director | 0.04% |
| Phillip Febbo | Chief Scientific & Medical Officer | 0.03% |
| Jens Holstein | Independent Director | 0.03% |
| Thomas Miller | Director | 0.02% |
| David Shafer | Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | Jens Holstein | Independent Director | Intent to Sell (Form 144) | -7,500 | $47.00 |
| 2026-09-20 | John Leite | Chief Commercial Officer for CLIA Business | Automatic Disposition | -4,015 | $40.00 |
| 2026-09-13 | Jens Holstein | Independent Director | Automatic Disposition | -5,000 | $40.95 |
| 2026-09-03 | Phillip Febbo | Chief Scientific & Medical Officer | Open Market Disposition | -13,110 | $42.89–43.66 |
| 2026-09-03 | Rebecca Chambers | Chief Financial Officer | Open Market Disposition | -3,652 | $42.81–43.71 |
| 2026-09-03 | Annie McGuire | Executive VP, General Counsel & Chief People Officer | Open Market Disposition | -3,254 | $42.79–43.67 |
| 2026-09-01 | Phillip Febbo | Chief Scientific & Medical Officer | Sale to Issuer | -3,639 | $44.88 |
| 2026-09-01 | Marc Stapley | Chief Executive Officer | Sale to Issuer | -8,782 | $44.88 |
| 2026-09-01 | Jonathan Wygant | Vice President | Sale to Issuer | -1,361 | $44.88 |
| 2026-09-01 | Rebecca Chambers | Chief Financial Officer | Sale to Issuer | -3,603 | $44.88 |
| 2026-09-01 | John Leite | Chief Commercial Officer for CLIA Business | Sale to Issuer | -3,961 | $44.88 |
| 2026-09-01 | Annie McGuire | Executive VP, General Counsel & Chief People Officer | Sale to Issuer | -3,215 | $44.88 |
| 2026-08-31 | Muna Bhanji | Independent Director | Automatic Disposition | -1,864 | $42.97 |
| 2026-06-17 | Karin Eastham | Independent Director | Automatic Disposition | -3,729 | $52.78–53.55 |
| 2026-06-10 | Karin Eastham | Independent Director | Other Acquisition | +5,272 | -- |
| 2026-06-10 | Evan Jones | Independent Director | Other Acquisition | +5,272 | -- |
| 2026-06-10 | Robert Epstein | Independent Chairperson | Other Acquisition | +5,272 | -- |
| 2026-06-10 | Jens Holstein | Independent Director | Other Acquisition | +5,272 | -- |
| 2026-06-10 | David Shafer | Director | Other Acquisition | +5,272 | -- |
| 2026-06-10 | Muna Bhanji | Independent Director | Other Acquisition | +5,272 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:26:05 · For reference only, not investment advice and not tailored to your situation.